A Large-Scale Genome-Wide Study of Gene-Sleep Duration Interactions for Blood Pressure in 811,405 Individuals from Diverse Populations
ABSTRACT
Although both short and long sleep duration are associated with elevated hypertension risk, our understanding of their interplay with biological pathways governing blood pressure remains limited. To address this, we carried out genome-wide cross-population gene-by-short-sleep and long-sleep duration interaction analyses for three blood pressure traits (systolic, diastolic, and pulse pressure) in 811,405 individuals from diverse population groups. We discover 22 novel gene-sleep duration interaction loci for blood pressure, mapped to genes involved in neurological, thyroidal, bone metabolism, and hematopoietic pathways. Non-overlap between short sleep (12) and long sleep (10) interactions underscores the plausibility of distinct influences of both sleep duration extremes in cardiovascular health. With several of our loci reflecting specificity towards population background or sex, our discovery sheds light on the importance of embracing granularity when addressing heterogeneity entangled in gene-environment interactions, and in therapeutic design approaches for blood pressure management.
Competing Interest Statement
C.L.M. has received funding from AstraZeneca not related to the current study. B.M.P. serves on the steering committee of the Yale Open Data Access Project funded by Johnson & Johnson. D.C. receives consultancy fees from Roche Diagnostics and Trimedics and speaker fees from Servier. D.A.L. has received support from Medtronic LTD and Roche Diagnostics for biomarker research not related to the current study. The remaining authors declare no competing interests.
Funding Statement
This project was largely supported by two grants from the U.S. National Heart, Lung, and Blood Institute (NHLBI), the National Institutes of Health, R01HL118305 and R01HL156991. Study-specific acknowledgements are included in the Supplementary Note. The research on the Million Veteran Program, was supported by award, CX001897 (PI A.M. Hung) from BLR&D, VA Office of R&D. This publication does not represent the views of the Department of Veteran Affairs or the United States Government. Acknowledgment of the Million Veteran Program leadership and staff contributions can be found in the Supplementary Note under MVP core acknowledgement.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work was approved by the Institutional Review Board of Washington University in St. Louis and complies with all relevant ethical regulations. For each of the participating cohorts, the appropriate ethics review board approved the data collection and all participants provided informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflict of Interest/Disclosures: C.L.M. has received funding from AstraZeneca not related to the current study. B.M.P. serves on the steering committee of the Yale Open Data Access Project funded by Johnson & Johnson. D.C. receives consultancy fees from Roche Diagnostics and Trimedics and speaker fees from Servier. D.A.L. has received support from Medtronic LTD and Roche Diagnostics for biomarker research not related to the current study. The remaining authors declare no competing interests.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Subject Area
- Addiction Medicine (399)
- Allergy and Immunology (708)
- Anesthesia (201)
- Cardiovascular Medicine (2923)
- Dermatology (249)
- Emergency Medicine (439)
- Epidemiology (12723)
- Forensic Medicine (12)
- Gastroenterology (827)
- Genetic and Genomic Medicine (4571)
- Geriatric Medicine (417)
- Health Economics (729)
- Health Informatics (2913)
- Health Policy (1069)
- Hematology (387)
- HIV/AIDS (924)
- Medical Education (423)
- Medical Ethics (115)
- Nephrology (468)
- Neurology (4341)
- Nursing (235)
- Nutrition (637)
- Oncology (2264)
- Ophthalmology (643)
- Orthopedics (258)
- Otolaryngology (324)
- Pain Medicine (278)
- Palliative Medicine (83)
- Pathology (500)
- Pediatrics (1196)
- Primary Care Research (495)
- Public and Global Health (6925)
- Radiology and Imaging (1524)
- Respiratory Medicine (915)
- Rheumatology (437)
- Sports Medicine (385)
- Surgery (486)
- Toxicology (60)
- Transplantation (210)
- Urology (179)